Zhu, H., Teng, G., Fan, W., Ji, J., Yang, W., Zhao, C., Huang, M., Wang, S., Li, Y., Shao, G., Cheng, H., Zeng, Y., Lv, W., Xu, H., Lu, L., Shao, H., Zhao, X., Gu, S., Lin, H., Zheng, W. (2025). Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: A multicenter, open-label, randomized, phase 2 study (CAP-ACE).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.lba522